URELLE (HYOSCYAMINE SULFATE, METHENAMINE, METHYLENE BLUE, PHENYL SALICYLATE, AND SODIUM PHOSPHATE, MONOBASIC, MONOHYDRATE) TABLET [MEDA PHARMACEUTICALS]

  • Home
  • URELLE (HYOSCYAMINE SULFATE, METHENAMINE, METHYLENE BLUE, PHENYL SALICYLATE, AND SODIUM PHOSPHATE, MONOBASIC, MONOHYDRATE) TABLET [MEDA PHARMACEUTICALS]

URELLE (HYOSCYAMINE SULFATE, METHENAMINE, METHYLENE BLUE, PHENYL SALICYLATE, AND SODIUM PHOSPHATE, MONOBASIC, MONOHYDRATE) TABLET [MEDA PHARMACEUTICALS]
PDF | XML
NDC 0037-6321-90
Set ID 1d80a11c-6f86-403b-85d4-32ec1924dbe9
Category HUMAN PRESCRIPTION DRUG LABEL
Packager Meda Pharmaceuticals
Generic Name
Product Class
Product Number
Application Number
View All Sections
  • DESCRIPTION:

    Urelle® tablets for oral administration are supplied as navy blue round tablets with “A-002” debossed on one side.

    Each Tablet Contains:

    Hyoscyamine Sulfate 0.12 mg

    Methenamine 81.0 mg

    Methylene Blue 10.8 mg

    Phenyl Salicylate 32.4 mg

    Sodium Phosphate Monobasic 40.8 mg

    INACTIVE INGREDIENTS:

    Corn Starch, Dicalcium Phosphate, FD&C Blue #2/Indigo Carmine Aluminum Lake, Magnesium Stearate, Microcrystalline Cellulose, Polyethylene Glycol, Polyvinyl Alcohol, Talc, Titanium Dioxide.

  • INDICATIONS and USAGE:

    Urelle® is indicated for the treatment of symptoms of irritative voiding. Indicated for the relief of local symptoms, such as inflammation, hypermotility, and pain, which accompany lower urinary tract infections. Indicated for the relief of urinary tract symptoms caused by diagnostic procedures.

  • CONTRAINDICATIONS:

    Hypersensitivity to any of the ingredients is possible. Risk - benefit should be carefully considered when the following medical problems exist: cardiac disease (especially cardiac arrhythmias, congestive heart failure, coronary heart disease, mitral stenosis); gastrointestinal tract obstructive disease; glaucoma; myasthenia gravis; acute urinary retention may be precipitated in obstructive uropathy (such as bladder neck obstruction due to prostatic hypertrophy).

  • WARNINGS:

    If rapid pulse, dizziness, or blurring of vision occurs, discontinue use immediately.

    Patients should be advised that urine will be colored blue when taking this medication. Do not exceed recommended dosage.

  • PRECAUTIONS:

    Cross sensitivity and/or related problems - patients intolerant of belladonna alkaloids or salicylates may be intolerant of this medication also. Delay in gastric emptying could complicate the management of gastric ulcers.

    Urelle® contains methylene blue. Methylene blue should generally NOT be given to patients taking serotonergic drugs.

    Drug Interactions:

    Although the exact mechanism of this drug interaction is unknown, methylene blue inhibits the action of monoamine oxidase A— an enzyme responsible for breaking down serotonin in the brain. It is believed that when methylene blue is given to patients taking serotonergic psychiatric medications, high levels of serotonin can build up in the brain, causing toxicity. This is referred to as Serotonin Syndrome. Signs and symptoms of Serotonin Syndrome include mental changes (confusion, hyperactivity, memory problems), muscle twitching, excessive sweating, shivering or shaking, diarrhea, trouble with coordination, and/or fever.

    Additional Information for Healthcare Professionals:

    Methylene blue can interact with serotonergic psychiatric medications and cause serious CNS toxicity.

    In emergency situations requiring life-threatening or urgent treatment with methylene blue (as described above), the availability of alternative interventions should be considered and the benefit of methylene blue treatment should be weighed against the risk of serotonin toxicity. If methylene blue must be administered to a patient receiving a serotonergic drug, the serotonergic drug must be immediately stopped, and the patient should be closely monitored for emergent symptoms of CNS toxicity for two weeks (five weeks if fluoxetine [Prozac] was taken), or until 24 hours after the last dose of methylene blue, whichever comes first.

    In non-emergency situations when non-urgent treatment with methylene blue is contemplated and planned, the serotonergic psychiatric medication should be stopped to allow its activity in the brain to dissipate. Most serotonergic psychiatric drugs should be stopped at least 2 weeks in advance of methylene blue treatment. Fluoxetine (Prozac), which has a longer half-life compared to similar drugs, should be stopped at least 5 weeks in advance.

    Treatment with the serotonergic psychiatric medication may be resumed 24 hours after the last dose of methylene blue.

    Serotonergic psychiatric medications should not be started in a patient receiving methylene blue. Wait until 24 hours after the last dose of methylene blue before starting the antidepressant.

    Educate your patients to recognize the symptoms of serotonin toxicity or CNS toxicity and advise them to contact a healthcare professional immediately if they experience any symptoms while taking serotonergic psychiatric medications or methylene blue.

  • ADVERSE REACTIONS

    To report SUSPECTED ADVERSE REACTIONS, contact Meda Pharmaceuticals Inc. at 1-877-999-8402 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.

  • DOSAGE and ADMINISTRATION:

    Adults – One tablet orally 4 times per day followed by liberal fluid intake.

    Pediatric – Dosage must be individualized by a physician for older children. Urelle® is not recommended for use in children 6 years of age or younger.

  • HOW SUPPLIED:

    Urelle® tablets for oral administration are supplied in child resistant bottles of 90 tablets (NDC 0037-6321-90).

    Store at controlled room temperature 20°-25°C (68°-77°F).

    Dispense in a tight, light resistant container as defined in the USP.

    KEEP THIS AND ALL DRUGS OUT OF THE REACH OF CHILDREN.

  • SPL UNCLASSIFIED SECTION

    Distributed by:
    Meda Pharmaceuticals®
    Somerset, New Jersey 08873-4120

    © 2014 Meda Pharmaceuticals Inc.

    MEDA PHARMACEUTICALS and URELLE are registered trademarks of Meda AB or a related entity.

    Rx Only

    IN-632110-01

    Rev. 07/2014

  • PRINCIPAL DISPLAY PANEL – BOTTLE LABEL

    NDC 0037-6321-90
    90 TABLETS

    Urelle®
    Urinary Antiseptic

    Rx only

    Distributed by:
    MEDA
    PHARMACEUTICALS®
    Somerset, New Jersey 08873-4120

    © 2018 Meda Pharmaceuticals Inc.

    MEDA PHARMACEUTICALS® and URELLE® are
    registered trademarks of Meda AB or a related entity.

    Description: Urelle® tablets for oral administration are supplied as navy blue
    round tablets with “A-002” debossed on one side.

    Each Tablet Contains:
    Hyoscyamine Sulfate     0.12 mg
    Methenamine      81.0 mg
    Methylene Blue      10.8 mg
    Phenyl Salicylate      32.4 mg
    Sodium Phosphate Monobasic      40.8 mg

    Dosage: Adults - one tablet orally 4 times per day followed by liberal fluid intake.
    Pediatric - Dosage must be individualized by a physician for older children.
    Urelle® is not recommended for use in children 6 years of age or younger.

    Precaution: Contains Methylene Blue and should NOT be taken with serotonergic
    psychiatric medications. For full product information see package insert.

    To report SUSPECTED ADVERSE REACTIONS, contact Meda Pharmaceuticals
    Inc. at 1-877-999-8402 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.

    Storage: Store at controlled room temperature 20°-25°C (68°-77°F). Dispense
    in a tight, light resistant container as defined in the USP.

    KEEP OUT OF THE REACH OF CHILDREN.

    Note: Patients should be advised that urine will be colored blue when taking
    this medication.

    LB-632110-02 Rev. 02/2018

    Urelle Antiseptic Label
  • INGREDIENTS AND APPEARANCE
    URELLE 
    hyoscyamine sulfate, methenamine, methylene blue, phenyl salicylate, and sodium phosphate, monobasic, monohydrate tablet
    Product Information
    Product TypeHUMAN PRESCRIPTION DRUGItem Code (Source)NDC:0037-6321
    Route of AdministrationORAL
    Active Ingredient/Active Moiety
    Ingredient NameBasis of StrengthStrength
    HYOSCYAMINE SULFATE (UNII: F2R8V82B84) (HYOSCYAMINE - UNII:PX44XO846X) HYOSCYAMINE SULFATE0.12 mg
    METHENAMINE (UNII: J50OIX95QV) (METHENAMINE - UNII:J50OIX95QV) METHENAMINE81 mg
    METHYLENE BLUE (UNII: T42P99266K) (METHYLENE BLUE CATION - UNII:ZMZ79891ZH) METHYLENE BLUE10.8 mg
    PHENYL SALICYLATE (UNII: 28A37T47QO) (PHENYL SALICYLATE - UNII:28A37T47QO) PHENYL SALICYLATE32.4 mg
    SODIUM PHOSPHATE, MONOBASIC, MONOHYDRATE (UNII: 593YOG76RN) (PHOSPHATE ION - UNII:NK08V8K8HR) SODIUM PHOSPHATE, MONOBASIC, MONOHYDRATE40.8 mg
    Inactive Ingredients
    Ingredient NameStrength
    STARCH, CORN (UNII: O8232NY3SJ)  
    ANHYDROUS DIBASIC CALCIUM PHOSPHATE (UNII: L11K75P92J)  
    FD&C BLUE NO. 2 (UNII: L06K8R7DQK)  
    MAGNESIUM STEARATE (UNII: 70097M6I30)  
    MICROCRYSTALLINE CELLULOSE (UNII: OP1R32D61U)  
    POLYETHYLENE GLYCOL, UNSPECIFIED (UNII: 3WJQ0SDW1A)  
    POLYVINYL ALCOHOL, UNSPECIFIED (UNII: 532B59J990)  
    TALC (UNII: 7SEV7J4R1U)  
    TITANIUM DIOXIDE (UNII: 15FIX9V2JP)  
    Product Characteristics
    ColorBLUEScoreno score
    ShapeROUNDSize11mm
    FlavorImprint Code A002
    Contains    
    Packaging
    #Item CodePackage DescriptionMarketing Start DateMarketing End Date
    1NDC:0037-6321-9090 in 1 BOTTLE; Type 0: Not a Combination Product01/12/2015
    Marketing Information
    Marketing CategoryApplication Number or Monograph CitationMarketing Start DateMarketing End Date
    Unapproved drug other01/12/2015
    Labeler - Meda Pharmaceuticals (051229602)
View All Sections

Related Drugs

Search DailyMed Drugs